GlassScriptPhysician profile
John R Carlson
NPI 1164429965
$2,025.53
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $589 · 2021: $790 · 2022: $97.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.09 | 2019-2021 | |
| Gilead Sciences, INC. | $321.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.05 | 2019-2022 | |
| Shionogi INC | $119.39 | 2019-2020 | |
| Janssen Biotech, INC. | $100.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $97.31 | 2019-2022 | |
| Pfizer INC. | $82.98 | 2019-2020 | |
| Daiichi Sankyo INC. | $65.93 | 2019-2020 | |
| Allergan, INC. | $54.96 | 2019-2020 | |
| Celgene Corporation | $45.87 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $31.26 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $20.60 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.81 | 2021 | |
| Boston Scientific Corporation | $15.85 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $14.93 | 2021 | |
| Axonics, INC. | $12.85 | 2020 | |
| Redhill Biopharma INC. | $11.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.